Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acceleron Pharma Inc Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option

Tuesday, 24 Sep 2013 04:30pm EDT 

Acceleron Pharma Inc announced the closing of its initial public offering of 6,417,000 shares of common stock, including 837,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments, at a public offering price of $15.00 per share, before underwriting discounts. Separately, in a concurrent, side-by-side private placement, Acceleron`s collaboration partner, Celgene Corporation, purchased 666,667 shares of common stock from Acceleron at the public offering price. Including the private placement to Celgene, the aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, were approximately $96.7 million. Citigroup and Leerink Swann acted as joint book-running managers for the offering. Piper Jaffray & Co. acted as lead manager and JMP Securities LLC acted as co-manager for the offering. 

Company Quote

-0.05 -0.18%
30 Jul 2015